Research Topics
| Mohammed AsmalSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant virusesMohammed Asmal
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
J Virol 85:5465-75. 2011..These findings suggest that despite the ability of SIV to mutate and adapt to multiple immunologic pressures during the course of infection, SIV envelope may not escape the binding of autologous antibodies that mediate ADCVI...- A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivityMohammed Asmal
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 6:e23673. 2011..These results support the potential utility of using a computational approach to examine large viral sequence data sets for functional signatures and indicate the importance of Envelope expression levels for efficient HIV transmission... - Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysWendy W Yeh
Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
J Virol 84:6018-32. 2010..They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies... - Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeysYue Sun
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Center for Life Science, 330 Brookline Avenue, Boston, MA 02115, USA
J Virol 85:6906-12. 2011..This final observation raises the possibility that the antibodies that mediate ADCC are a subset of the antibodies detected in a binding assay and arise within weeks of infection... 
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in MonkeysNorman L Letvin
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Sci Transl Med 3:81ra36. 2011..This study begins to elucidate the mechanisms of vaccine protection against immunodeficiency viruses and highlights the need to analyze these immune and genetic correlates of protection in future trials of HIV vaccine strategies...- Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolateWendy W Yeh
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, CLS 1043, 3 Blackfan Circle, Boston, MA 02115, USA
J Virol 83:2686-96. 2009.... - In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomesMohammed Asmal
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
PLoS ONE 7:e48234. 2012..Ultimately, understanding how serpins, such as hep-ATIII, regulate host responses during HIV infection may reveal new avenues for therapeutic intervention... - Inhibition of HCV by the serpin antithrombin IIIMohammed Asmal
Division of Viral Pathogenesis, BIDMC, Boston, MA 02215, USA
Virol J 9:226. 2012..We have recently shown that ATIII, a serine protease inhibitor (serpin), has broad antiviral properties... - Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replicationJames B Whitney
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
PLoS ONE 6:e18589. 2011..These findings suggest a central role for serpins in the host innate anti-viral response. Host factors such as PTGS2 elicited by ATIII treatment could be exploited in the development of novel anti-viral interventions...